口服避孕药类型及使用时长对IVF/ICSI新鲜与累积活产率的影响
这项回顾性研究纳入2009至2017年间4116例首次接受卵巢刺激的18-45岁不孕女性,比较口服避孕药(OCP)预处理(n=3517)与未预处理(n=599)的新鲜及累积活产率。结果显示,使用12-30天OCP并在停药5天后启动刺激,不影响临床妊娠、活产或累积活产;两种OCP类型间也无差异。
要点
- OCP预处理12-30天且停药5天不影响IVF/ICSI的活产和累积活产率。
- OCP使用与获卵数小幅增加独立相关(β 0.22,95%CI 0.12-0.31)。
- 屈螺酮和去氧孕烯两种OCP在刺激和临床结局上无差异。
核心结论
- IVF/ICSI前使用12-30天OCP进行周期规划不降低活产率和累积活产率。
研究设计与样本
- 回顾性分析,2009年1月至2017年12月单中心4116例18-45岁首次卵巢刺激的不孕女性,OCP组3517例,无OCP组599例。
主要发现
- OCP组与无OCP组的累积活产率分别为32.4%和31.6%(P=0.712)。
- 调整混杂后,OCP组新鲜胚胎移植后活产概率相似(ORadj 0.89,95%CI 0.69-1.15)。
- 调整后OCP组新鲜及冻融胚胎累积活产概率相似(ORadj 0.94,95%CI 0.73-1.21)。
- OCP使用与获卵数小幅增加独立相关(β 0.22,95%CI 0.12-0.31)。
- 屈螺酮和去氧孕烯两组间卵巢刺激和临床结局无差异。
关键数值与推荐
- OCP方案为炔雌醇30μg/去氧孕烯150μg或炔雌醇30μg/屈螺酮3mg,使用12-30天,停药5天后启动刺激。
临床怎么用
- 临床可安全使用12-30天OCP进行IVF/ICSI周期规划,无需担心降低活产率。
局限性
- 回顾性研究,不能排除混杂偏倚和选择偏倚。
- OCP非随机分配,存在选择偏倚可能。
- 仅使用两种OCP及固定方案,更长用药、其他类型或不同停药间隔的效果未知,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are there any differences in the fresh (LB) and cumulative live birth rates (CLBR) of women undergoing controlled ovarian stimulation (COS) for IVF/ICSI following pretreatment with different types of oral contraceptive pills (OCP) for different durations as compared to no-OCP? SUMMARY ANSWER: OCP administration for an interval of 12- to 30-day treatment period and with a 5-day washout period does not affect clinical pregnancy, LB nor cumulative LB in patients undergoing COS for an IVF cycle. WHAT IS KNOWN ALREADY: The use of OCP is an effective way of treatment planning in IVF/ICSI cycles, but published evidence about its effect on pregnancy and LBR is inconsistent, some studies finding decreased rates but others no difference. STUDY DESIGN, SIZE, DURATION: This is a retrospective analysis carried out in a University-affiliated tertiary centre between January 2009 and December 2017. Overall, 4116 infertile women between 18 and 45 years, who underwent their first ovarian stimulation cycle in our centre, were included. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients were categorised into two groups as receiving OCP (n = 3517) or not (no OCP, n = 599). All patients with OCP pretreatment initiated controlled ovarian stimulation (COS) 5 days post-pill. Overall, two types of OCP were used at the study's centre: ethinylestradiol (EE) 30 μg/desogestrel 150 μg, a third-generation progesterone; or EE 30 μg/drospirenone 3 mg, a fourth-generation progestin with mild antiandrogenic activity. MAIN RESULTS AND THE ROLE OF CHANCE: A total of n = 4116 patients were analysed, (OCP n = 3517 and non-OCP n = 599). The use of OCP was independently associated with a small increase in the number of oocytes retrieved after adjusting for age, BMI, use of OCP, cause of infertility, initial dose (IU), type of gonadotropin, stimulation days, total stimulation units (total IU) (β 0.22, 95% CI 0.12-0.31). Cumulative LBRs were comparable between groups OCP versus non-OCP (32.4 versus 31.6%, P = 0.712). Following adjustment for age, BMI, infertility diagnosis, starting and total dose, type of gonadotropin, total days of stimulation, type of insemination, number of oocytes retrieved, day of transfer and number of embryos transferred in a multiple logistic analysis, patients using OCPs had a similar probability of achieving a LB as compared with patients not-using OCPs following fresh embryo transfer (ORadj 0.89, 95% CI 0.69-1.15) and a similar probability for CLBR after the use of fresh and frozen embryos (ORadj 0.94, 95% CI 0.73-1.21). No differences were observed in ovarian stimulation and clinical outcomes between drospirenone and desogestrel OCP groups. LIMITATIONS, REASONS FOR CAUTION: Limitations are related to the retrospective nature of the study; despite the sample size, the adjustments and the multivariable regression analysis conducted, we cannot exclude the presence of confounding bias. OCP administration was not randomly assigned, not allowing to exclude the presence of selection bias. Lastly, we only used two types of OCP with durations and washout periods as per institution protocol. Therefore, we cannot exclude that longer duration of administration, a different type of OCP or different pill-free interval might have had an alternative effect on LBR or CLBR; thus, the generalizability of this study's results should be considered with caution. WIDER IMPLICATIONS OF THE FINDINGS: Our study provides reassuring evidence that the use of 12-30 days OCP for cycle programming, prior to IVF, does not decrease the chance of live birth and cumulative live birth rates. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used for this study. This research was performed under the auspices of 'Càtedra d'Investigació en Obstetrícia I Ginecologia' of the Department of Obstetrics, Gynaecology and Reproductive Medicine, Hospital Universitario Dexeus, Universitat Autònoma de Barcelona. The authors report no conflict of interest associated with the current study. TRIAL REGISTRATION NUMBER: NA.
引用
- Montoya-Botero P, Martinez F, Rodríguez-Purata J, et al. The effect of type of oral contraceptive pill and duration of use on fresh and cumulative live birth rates in IVF/ICSI cycles. Hum Reprod. 2020. PMID: 32163564. doi:10.1093/humrep/dez299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。